

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA

ABN 84 152 713 098

FINANCIAL REPORT

for the year ended 30 June 2017

CONTENTS

	Page
1. Directors' Report	3
2. Auditor's Independence Declaration	8
3. Financial Report	
Statement of Profit or Loss and Other Comprehensive Income	9
Statement of Changes in Equity	10
Statement of Financial Position	11
Statement of Cash Flows	12
Notes to the Financial Statements	13
4. Directors' Declaration	17
5. Independent Auditor's Report to the Members	18

This Financial Report covers National Stem Cell Foundation of Australia ('the Company') as an individual entity. National Stem Cell Foundation of Australia is a Company limited by guarantee, incorporated and domiciled in Australia.

The Company's registered office and principal place of business is:

Suite 5
242 Hawthorn Road
Caulfield Victoria 3162

A description of the nature of the Company's operations and its principal activities is included in the Directors' Report on pages 3 to 7 which is not part of this Financial Report.

The Financial Report was authorised for issue by the directors on 14 August 2017. The directors have the power to amend and reissue the Financial Report.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

The directors present their report together with the Financial Report of National Stem Cell Foundation of Australia for the year ended 30 June 2017 and the Auditor's Report thereon.

Directors

The directors of the Company at any time during or since the end of the year are:

<i>Name</i>	<i>Age</i>	<i>Period of directorship, special responsibilities, experience, other current directorships and former directorships in the last three years. Note: FARM is Finance, Audit and Risk Management Committee and SE is Science and Ethics Committee</i>
<p>Dr Graeme Blackman AO, PhD, BSc (Hons), BD, MTheol, FTSE, FRACI, FAICD, FloD (Non-Executive Director, Chairman, Member of FARM Committee)</p>	71	<p>Independent non-executive director and Chairman of the Company, appointed 17 August 2011. Dr Blackman is a former Professor of Pharmaceutical Chemistry at the Victorian College of Pharmacy. He is a non-executive director of IDT Australia Ltd, an Australian Securities Exchange (ASX) listed public company operating in the pharmaceutical industry. He was a director of the Australian Stem Cell Centre. He has been or continues to be a member of various Commonwealth and State advisory committees and working groups in pharmaceuticals and biotechnology, including the Australian Biotechnology Advisory Council, the Pharmaceutical Industry Working Group and the Pharmaceutical Industry Strategy Group. He chaired the Australian Government's Pharmaceuticals Industry Action Agenda, which developed a policy framework for the industry over a ten year period.</p>
<p>Emeritus Professor Graham Macdonald AM, MD, BS, BSc (Med), FRACP, FRCP, FANZCC (Non-Executive Director, Deputy Chairman, Chairman of SE Committee)</p>	80	<p>Independent non-executive director and Deputy Chairman of the Company appointed 29 September 2011. Professor Macdonald brings a wealth of experience in clinical medicine, basic biomedical science and in the field of licensing and commercialisation to the Company. He has had an outstanding career first as an academic nephrologist, and then moving into the pharmaceutical industry with Merck Sharp and Dohme (Australia). Graham is currently a director and Chairman of Vectus Biosciences Limited and director and chairman of Stem Cells Limited. In June 2012 Professor Macdonald received an Australian Queen's Birthday Honour in the General Division of the Order of Australia for "service to biomedical research in the areas of hypertension and renal disease, to medical education, to the promotion and awareness raising of organ donation, and as a mentor".</p>
<p>Emeritus Professor Richard Smallwood AO, MB, BS, MD, FRACP, FRCP, FACP (Hon), DMedSci (Hon), FAHMS (Hon) (Non-Executive Director, Member of SE Committee)</p>	80	<p>Independent non-executive director appointed 17 August 2011. Professor Smallwood is Emeritus Professor of Medicine, University of Melbourne. As Professor of Medicine within the University of Melbourne, he was Head of the Department of Medicine, Chairman of the Division of Medicine and Director of Gastroenterology at the Austin and Repatriation Medical Centres. Professor Smallwood was President of the Royal Australasian College of Physicians from 1996 to 1998 and was Chief Medical Officer of Australia from 1999 to 2003. Professor Smallwood has served as a chair of a large number of organisations including the National Health and Medical Research Council (NHMRC), the National Influenza Pandemic Advisory Council, the National Health Information Management Advisory Council, the National Health Priority Action Council, the National Blood Authority and the Ministerial Taskforce for Cancer in Victoria. Professor Smallwood was President of the Australian Medical Council from 2008 to 2013. He was until 2010 a member of the Board of Governance of the Victorian Health Promotion Foundation and, until 2009, a director of the Murdoch Children's Research Institute. From 2013 he has been Chair of the Campus Council of Melbourne Children's. He was a director of the Australian Stem Cell Centre.</p>
<p>Mr Stuart Gooley BComm (Melb), FCA, FCPA (Non-Executive Director, Chairman of FARM Committee)</p>	72	<p>Independent non-executive director and Chairman of the Finance, Audit and Risk Management Sub-committees appointed 17 August 2011. Mr Gooley had a 42 year period in the accounting profession with Arthur Andersen and Ernst & Young, and retired from public practice in 2008. During his career he was the Australian head of Andersen's Accounting and Audit practice and the Asia Pacific Risk Management Practice Director. Mr Gooley was the Victorian State President of CPA Australia in 1994, and served on the Australian Auditing and Assurance Standards Board and the International Auditing Practices Committee. Outside of the accounting profession he has served on the board of two educational institutions, and is currently a director of Lahaina Holdings Pty Ltd, Tai Tam Investments Pty Ltd and Wilson Transformer Company. He is also a member of the resources committee of the Royal Australian College of Surgeons. He was a director of the Australian Stem Cell Centre.</p>

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Name	Age	<i>Period of directorship, special responsibilities, experience, other current directorships and former directorships in the last three years. Note: FARM is Finance, Audit and Risk Management Committee and SE is Science and Ethics Committee</i>
<p>Dr Peter Riddles BSc (Hons), PhD, Grad Dip Bus (Management), FAICD (Non-Executive Director) Resigned 27 February 2017</p>	63	<p>Independent non-executive director appointed 29 September 2011 and resigned 27 February 2017. Dr Riddles has extensive experience in biotechnology having served as director on many start-up enterprises, and having worked with universities and with the private sector. He is presently Chairman of the Griffith University Enterprise Board and is a Board Member of the Hear and Say Centre, and the CSIRO. He is presently a member of the Entrepreneurs Program Committee of Innovation and Science Australia, and the Director of ViciBio Pty Ltd, a company that provides services to organisations involved in science, technology commercialisation and innovation. Earlier he has served on diverse boards in the private and public sector concerning innovation and biotechnology including Innovation Australia, the Industry Research and Development Board, and the Australian Stem Cell Centre.</p>
<p>Mr David Collins MEng, MBA, CA, GAICD (Non-Executive Director, Member of FARM Committee)</p>	52	<p>Independent non-executive director and member of the Finance, Audit and Risk Management Sub-committees appointed 16 December 2011. Mr Collins is a partner in an accountancy and consultancy firm and has previously held senior executive positions in companies in Europe and the UK within the media industry. Mr Collins was Chief Executive Officer of the Australian Stem Cell Centre from September 2009 until November 2011.</p>
<p>Dr Karin Tiedemann OAM, MBBS, FRACP (Non-Executive Director, Member of SE Committee)</p>	69	<p>Independent non-executive director appointed 15 December 2014. Dr Tiedemann practiced for more than 30 years as a paediatric haematologist and oncologist in the Children's Cancer Centre at The Royal Children's Hospital (RCH) in Melbourne prior to retirement from clinical practice in 2014. Dr Tiedemann established the haemopoietic stem cell transplant program at RCH in 1981, heading the program until 2011. She was pivotal in obtaining the support of the Bone Marrow Donor Institute in establishing an umbilical cord blood stem cell bank at the RCH thus expanding donor availability to many children previously unable to locate a donor and therefore unable to proceed to transplantation for recurrent leukaemia or other lethal marrow disorders. She was a founding member of the Australian and New Zealand Children's Haematology and Oncology Group, served on the executive and on subcommittees, contributing to advances in treatment that have resulted not only in high cure rates but also a lowering of the long term side effects of cancer treatment for infants, children and adolescents. Dr Tiedemann is the Medical Director of the BMDI Cord Blood Bank, a member of the BMDI CBB Management Committee and of Auscord, the national network of cord blood banks. She served on the Clinical Ethics Response Group at RCH and on the Ethics Committee of the Australian Bone Marrow Donor Registry.</p>
<p>Associate Professor Caroline Gargett PhD (Non-Executive Director, Member of SE Committee)</p>	65	<p>Independent non-executive director appointed 15 December 2014. Associate Professor Gargett is currently Deputy Director (Women's Health) at the Ritchie Centre, Hudson Institute of Medical Research where she heads the Endometrial Stem Cell Biology Group. She is also a National Health & Medical Research Council (NHMRC) Senior Research Fellow. She leads collaborative research with CSIRO Manufacturing, Flinders and Warwick Universities investigating the use of endometrial mesenchymal stem cells for regenerative medicine application in urogynaecology, and is actively working towards clinical translation. Associate Professor Gargett has served as President of the Australasian Society for Stem Cell Research (2013-2014) and co-led the successful bid to bring the International Society for Stem Cell Research 2018 conference to Melbourne. She serves on the Editorial Boards of Scientific Reports, Biology of Reproduction and Reproductive Sciences.</p>

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Company Secretary and Executive Officers

<i>Name</i>	<i>Age</i>	<i>Period of office, special responsibilities and experience</i>
Mr Graeme Mehegan BBus(Acc), FCPA, FCIS (Company Secretary, Member of FARM Committee)	62	Mr Mehegan was appointed Company Secretary 8 November 2011. Mr Mehegan was Chief Financial Officer for the Australian Stem Cell Centre from August 2009 until November 2011. He was Chief Financial Officer and Company Secretary for Pioneer Electronics Australia from January 2001 until March 2008 and prior to that held senior financial roles including the position of Company Secretary with Random House Australia and Pitman Publishing, both in the book publishing industry.
Ms Julia Mason MBA (Chicago), FFin, MAICD (Executive Officer, Member of FARM and SE Committees)	48	Executive Officer appointed on 19 February 2015. Ms Mason has a 20 year plus career focused on creating growth and value, in the private and not for profit sectors in both Australia and Asia, across the advertising, finance and oil industries. She has held senior commerce and finance positions at Sensis and BP. Ms Mason is a director of the Transport Accident Commission (TAC) Board of Victoria and was previously Chairman of the Victorian State Emergency Services (VICSES), One in Five, and a director with VicUrban. Ms Mason has also lectured in corporate finance in the masters program with FinSia, the former Securities Institute of Australia. Ms Mason was previously a director with Same Business Different Outcome (SBDO), a Melbourne-based private equity business sourcing operational expertise and capital to back growth businesses.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Principal activities

The National Stem Cell Foundation of Australia is an Australian Tax Office (ATO) registered Health Promotion Charity dedicated to promoting the study and responsible use of stem cells to reduce the burden of disease.

The Foundation's priorities are:

- Supporting research that pursues cures for not yet treatable diseases
- Building a community of people with a shared interest in stem cell science
- Providing the Australian public with objective, reliable information on both the potential and risks of stem cell medicine.

Short-term objectives

The Company funds a broad program of activities that will support Stem Cell Science in Australia. During the year ended 30 June 2017 \$130,792 (2016 \$174,751) was contributed towards health promotion activities and since the formation of the Foundation contributions now total \$846,817.

The Company is also taking steps to increase fundraising income from various sources.

Long-term Objectives

The Company's long-term objectives are to:

- Pursue the cures for not yet treatable diseases and illnesses using stem cell technology and regenerative medicine techniques by supporting research activities in these areas.
- Provide resources to develop objective information and to educate and inform the Australian public on stem cell technology and regenerative medicine including its risks, achievements, benefits and overall technical progress.

Strategy for achieving short and long-term objectives

To achieve these objectives, the Company will draw heavily on the experience of its Board of Directors, Executive Officer and Company Secretary who (as a group) have considerable and varied experience in medical research, business management and finance.

The Board will seek to appoint experts in various fields where specialised expertise and scientific advice is required including:

- Investment strategy
- Website development and marketing
- Promotion and public relations

Given the nature of its activities and the Health Promotion Charity status of the Company, the Board has successfully obtained some services on a pro-bono basis but in other cases has found it necessary to enlist external paid consultants.

This year the Foundation provided philanthropic financial support for the following health promotion activities in support of Australian stem cell science:-

- **Continued with its Awarding** of the annual NSCFA Metcalf Prizes for mid-career researchers working in stem cell research in Australia
- **Provided support** for PhD students and Early Career Researchers to attend and present at the two Australasian Society of Stem Cell Researchers Conferences held at Margaret River and Sydney
- **Sponsored** the 25th New South Wales Stem Cell Network Workshop on Stem Cells and Neurological Injuries
- **Provided** funding for the review and updating of the document Snapshot of Research Funding in Australia which is available on the Company's website

Additionally during the year the Foundation published 5 newsletters.

Directors' meetings

The number of directors' meetings (including meetings of committees of directors) and number of meetings attended by each of the directors of the Company during the year were:

	Directors' Meetings		Finance, Audit and Risk Management Sub-Committee Meetings		Science and Ethics Sub-Committee Meetings	
	Attended (ii)	Held (i)	Attended (ii)	Held (i)	Attended (ii)	Held (i)
Dr G Blackman	4	4	4	6	-	-
Emeritus Prof G Macdonald	4	4	-	-	4	4
Emeritus Prof R Smallwood	2	4	-	-	2	4
Dr P Riddles	2	3	-	-	-	-
Mr S Gooley	3	4	6	6	-	-
Mr D Collins	4	4	6	6	-	-
Dr K Tiedemann	3	4	-	-	3	4
Assoc Prof C Gargett	4	4	-	-	4	4

- (i) Represents the number of meetings held during the time that the director held office or was a member of the committee during the year.
- (ii) Director either attended or their duly appointed alternate director attended on their behalf.

The Finance, Audit and Risk Management Sub-committee is chaired by Mr S Gooley and its role is to review the implementation of the risk management processes, financial reporting, internal control and management of financial risks, the audit process, and the Company's process for monitoring compliance with laws and regulations.

The Foundation's Science and Ethics Committee is chaired by Emeritus Prof G Macdonald. It is responsible for providing the Board with information and guidance on the current state of stem cell science, research activities in the area, ethical issues that arise and how they have been dealt with by regulatory bodies or governments. The Committee also oversees the Foundation's major research support activity, the selection of recipients of two Metcalf prizes annually for mid-career researchers in stem cell science and is responsible for replying to enquiries from members of the public seeking information about stem cell treatments.

Contribution in Winding Up

The Company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the Company is wound up the constitution states that each member is required to contribute a maximum of \$100 each towards meeting any outstanding obligations of the entity. At 30 June 2017, the total amount that members of the Company are liable to contribute if the Company is wound up is \$800.

Auditors' independence declaration

A copy of the auditors' independence declaration as required under section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* is set out on page 8.

Dated at Melbourne this 14th day of August 2017.

Signed in accordance with a resolution of the directors.



Dr Graeme Blackman
(Chairman)



Grant Thornton

The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF NATIONAL STEM CELL FOUNDATION OF AUSTRALIA

In accordance with the requirements of section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012*, as lead auditor for the audit of National Stem Cell Foundation of Australia for the year ended 30 June 2017, I declare that, to the best of my knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the audit.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

Eric W Passaris

Eric Passaris
Partner - Audit & Assurance

Melbourne, 14 August 2017

grantthornton.com.au

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME for the year ended 30 June 2017

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

Statement of profit or loss and other comprehensive income for the year ended 30 June 2017	Note	Year Ended 30 June 2017	Year Ended 30 June 2016
		\$	\$
Revenues	2	772,594	287,669
Administrative costs	3	(142,862)	(130,087)
Promoting stem cell science and projects	3	(130,792)	(174,751)
Gain/(Loss) on disposal of investments		(8,650)	9,537
Profit/(Loss) before income tax		490,290	(7,632)
Income tax expense		-	-
Profit/(Loss) for the year		490,290	(7,632)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Changes in the fair value of available for sale financial assets		255,773	(236,969)
Other comprehensive income for the year		255,773	(236,969)
Total comprehensive income for the year		746,063	(244,601)

This Statement of profit or loss and other comprehensive income is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

STATEMENT OF CHANGES IN EQUITY

for the year ended 30 June 2017

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA ABN 84 152 713 098

Statement of changes in equity	AFS Financial	Retained	Total Equity
For the year ended 30 June 2017	Instrument	Earnings	
	Reserve		
	\$	\$	\$
Total equity at the beginning of the financial year	61,350	4,053,461	4,114,811
Profit for the year	-	490,290	490,290
Changes in fair value of available for sale financial assets	255,773	-	255,773
Total comprehensive income for the year	255,773	490,290	746,063
Total equity at the end of the financial year	317,123	4,543,751	4,860,874
For the year ended 30 June 2016	AFS Financial	Retained	Total Equity
	Instrument	Earnings	
	Reserve		
	\$	\$	\$
Total equity at the beginning of the financial year	298,319	4,061,093	4,359,412
Loss for the year	-	(7,632)	(7,632)
Changes in fair value of available for sale financial assets	(236,969)	-	(236,969)
Total comprehensive income for the year	(236,969)	(7,632)	(244,601)
Total equity at the end of the financial year	61,350	4,053,461	4,114,811

This Statement of changes in equity is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

Statement of financial position

as at 30 June 2017

	Note	2017	2016
		\$	\$
Current assets			
Cash and cash equivalents	4	1,108,704	659,873
Trade receivables and prepayments	5	128,776	112,787
Investments	6	3,650,392	3,398,350
Total current assets		4,887,872	4,171,010
Non current assets			
Plant & Equipment		-	138
Total non current assets		-	138
Total assets		4,887,872	4,171,148
Current liabilities			
Trade and other payables	7	25,939	55,125
Short-term employee benefits		1,059	1,212
Total current liabilities		26,998	56,337
Total liabilities		26,998	56,337
Net assets		4,860,874	4,114,811
Equity			
Retained earnings	8	4,543,751	4,053,461
Other reserves	8	317,123	61,350
Total equity		4,860,874	4,114,811

This Statement of financial position is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

Statement of cash flows

for the period ended 30 June 2017

Note

Year Ended
30 June 2017Year Ended
30 June 2016

		\$	\$
Cash flows from operating activities			
Profit / (Loss) after related income tax		490,290	(7,632)
Adjustments for:			
Depreciation & Amortisation		138	383
Change in assets and liabilities:			
Trade and other receivables		(15,989)	33,210
Short term employee benefits		(153)	704
Trade and other payables		(29,186)	41,944
Net cash Inflow / (outflow) from operating activities		445,100	68,609
Cash flows from investing activities			
Proceeds from sales of investments		400,000	1,188,000
Payments for new investments		(396,269)	(800,000)
Net cash inflow / (outflow) from investing activities		3,731	388,000
Cash flows from financing activities			
Net cash inflow from financing activities		-	-
Net Increase/(Decrease) in cash held			
Cash and cash equivalents at the beginning of the period		659,873	203,264
Cash and cash equivalents at the end of the period	4	1,108,704	659,873

This Statement of cash flows is to be read in conjunction with the Notes to the Financial Statements set out on pages 13 to 16.

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

1 Summary of significant accounting policies

The principal accounting policies set out below have been consistently applied, unless otherwise stated.

a) Basis of preparation

This general purpose Financial Report has been prepared in accordance with Australian Accounting Standards – Reduced Disclosure Requirements, other authoritative pronouncements of the Australian Accounting Standards Board and the *Australian Charities and Not-for-profits Commission Act 2012*.

These financial statements have been prepared under the historical cost convention, modified by the revaluation of available-for-sale financial assets.

b) Foreign currency

Functional and presentation currency

Items included in the financial statements of the Company are measured and presented in Australian dollars.

Transactions and balances

Foreign currency transactions are initially translated into Australian currency using the exchange rates prevailing at the date of each transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

c) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will follow and the revenue can be reliably measured. All revenue is stated net of the amount of goods and services tax (GST).

Donations revenue:

Donations are only brought to account when the funds are received into the bank account, that is, when control over the funds is established, or the right to receive the funds has been recognised.

Investment revenue:

Receipts associated with dividends are recognised as revenue when the right to receive payment has been established.

Interest revenue:

Interest revenue is recognised when the right to receive the revenue has been established.

Other revenue:

Other revenue is recognised when the right to receive the revenue has been established.

Franking credits:

Franking credits are recognised when the right to receive the revenue has been established and can be reliably measured.

d) Income tax

The Company has received a private ruling from the Australian Taxation Office (ATO) to receive exemption from income tax pursuant to the provisions of section 50-5 of the *Income Tax Assessment Act 1997*. The Company currently considers that it will continue to be exempt under the self assessment system applying under section 50-5 of the *Income Tax Assessment Act 1997*.

e) Trade and other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial period and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition.

f) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the amount of GST incurred is not recoverable from the ATO. In this case it is recognised as part of the cost of acquisition of the asset or as part of an item of expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the balance sheet.

The GST components of cash flows arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cash flow.

g) Cash and cash equivalents

For cash flow statement presentation purposes, cash and cash equivalents includes deposits at call with financial institutions and other highly liquid investments with short periods to maturity that are readily convertible to cash on hand and are subject to an insignificant risk of changes in value.

h) Investments

Investments are categorised as available-for-sale assets. After initial recognition, available-for-sale assets are measured at fair value with gains or losses being recognised as a separate component of equity until the investment is derecognised or until the investment is determined to be impaired, at which time the cumulative gain or loss previously reported in equity is recognised in profit or loss.

i) Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances. In the preparation of the financial statements for the period ended 30 June 2017, there have been no areas involving a high degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements.

	Note	Year Ended 30 June 2017	Year Ended 30 June 2016
		\$	\$
2 Revenue			
Donations and bequests		522,048	26,676
Income from investments		237,636	250,047
Interest income		12,910	10,926
Other		-	20
Total revenue		772,594	287,669
3 Expenses			
Expenditure classified by function			
Administrative Expenses			
- Salaries and on-costs		69,838	69,794
- Directors expenses		3,425	3,471
- Professional fees		49,292	31,113
- Insurance		3,231	3,627
- Other administration expenses		17,076	22,082
Total Administrative Expenses		142,862	130,087
Expenses incurred in promoting Stem Cell Science including projects		130,792	174,751
Total expenditure		273,654	304,838
4 Cash and cash equivalents			
Cash at bank and on hand		157,265	208,861
Term Deposits		951,439	451,012
Total cash and cash equivalents		1,108,704	659,873
The above figures are reconciled to cash at the end of the financial period as shown in the Statement of Cash Flows.			
5 Receivables			
Receivables		128,776	112,787
Total receivables		128,776	112,787

	Notes	Year Ended 2017	Year Ended 2016
		\$	\$
6 Investments			
Available-for-sale financial assets at original value		3,333,269	3,337,000
Changes in fair value of available for sale financial assets		317,123	61,350
Total investments		3,650,392	3,398,350
7 Trade and other payables			
Trade payables		25,939	55,125
Total trade and other payables		25,939	55,125
8 Equity			
Available-for-Sale financial assets reserve (i)		317,123	61,350
Retained profits		4,543,751	4,053,461
Total equity		4,860,874	4,114,811

(i) Available-for-sale financial assets reserve

Changes in the fair value of investments classified as available-for-sale financial assets are recognised in other comprehensive income, as described in note 1(h) and accumulated in a separate reserve within equity. Amounts are reclassified to profit or loss when the associated assets are sold or impaired.

9 Related party disclosures

Directors and other key management personnel

Apart from the amounts and issues disclosed in this note, there were no other transactions or balances with related parties during or at the end of the financial period.

Key management personnel compensation

Total key management personnel remuneration	69,838	69,794
---	--------	--------

Controlling entities

From incorporation of the Company in August 2011 the sole members of the company are the directors of the company.

10 Lease commitments

The company's future minimum operating lease payments are as follows:

	Minimum lease payments due			
	Within 1 year	1 to 5 years	After 5 years	Total
	\$	\$	\$	\$
30 June 2017	-	-	-	-
30 June 2016	-	-	-	-

NATIONAL STEM CELL FOUNDATION OF AUSTRALIA. ABN 84 152 713 098

11 Members' guarantee

The Company was incorporated on 17 August 2011 as a Company limited by guarantee and not having a share capital. If the Company is wound up, the Constitution states that current Members (of which there are seven), and any persons whom were Members within the last 12 months immediately prior, are required to contribute an amount determined by the Company, but not exceeding \$100, to meet the outstanding obligations of the Company, if required.

12 Events occurring after the reporting date

There have been no events subsequent to balance date of a material nature.

13 Contingent liabilities

There are no contingent liabilities as at yearend.

Directors' Declaration

In the directors' opinion:

- (a) the Financial Statements, comprising the Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position, Statement of Cash Flows and Statement of Changes in Equity, and accompanying notes, as set out on pages 9 to 16 are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, and:
 - (i) comply with Australian Accounting Standards – Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Regulations 2013*; and
 - (ii) give a true and fair view of the Company's financial position as at 30 June 2017 and of its performance for the financial period ended on that date; and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Dr Graeme Blackman
Chairman

Melbourne
14 August 2017



The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NATIONAL STEM CELL FOUNDATION OF AUSTRALIA

Report on the Audit of the Financial Report

Auditor's Opinion

We have audited the accompanying financial report of National Stem Cell Foundation of Australia (the "Company"), which comprises the statement of financial position as at 30 June 2017, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and the directors' declaration.

In our opinion, the financial report of National Stem Cell Foundation of Australia has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- a giving a true and fair view of the Registered Entity's financial position as at 30 June 2017 and of its financial performance for the year then ended; and
- b complying with Australian Accounting Standards- Reduced Disclosure Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Auditor's Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of the Directors for the Financial Report

The Directors of the Company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

Eric W Passaris

Eric Passaris
Partner - Audit & Assurance

Melbourne, 14 August 2017